Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).
Verkerk K, Zeverijn LJ, van de Haar J, Roepman P, Geurts BS, Spiekman AC, van der Noort V, van Berge Henegouwen JM, Hoes LR, van der Wijngaart H, Jansen AML, de Leng WWJ, Gelderblom AJ, Verheul HMW, Voest EE. Verkerk K, et al. Among authors: van der noort v. ESMO Open. 2025 Jan 7;10(1):104112. doi: 10.1016/j.esmoop.2024.104112. Online ahead of print. ESMO Open. 2025. PMID: 39778224 Free article.
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, Guerrero Paez C, Mol L, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van Schaik-van de Mheen C, Tol J, Tromp-van Driel CS, Vrijaldenhoven S, van Leeuwen-Stok AE, Konings IR, Jager A; SONIA Study Consortium. Sonke GS, et al. Among authors: van der noort v. Nature. 2024 Dec;636(8042):474-480. doi: 10.1038/s41586-024-08035-2. Epub 2024 Nov 27. Nature. 2024. PMID: 39604725 Clinical Trial.
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
van der Wel JWT, Jebbink M, van den Broek D, Steinbusch LC, Theelen WSME, Ruiter G, Buikhuisen W, Burgers JA, Baas P, Vermeulen M, van der Noort V, Hashemi SMS, Bosch LJW, Monkhorst K, Smit EF, Boelens MC, de Langen AJ. van der Wel JWT, et al. Among authors: van der noort v. Lung Cancer. 2024 Dec;198:107972. doi: 10.1016/j.lungcan.2024.107972. Epub 2024 Sep 28. Lung Cancer. 2024. PMID: 39556978
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study.
Stockem CF, Einerhand SMH, Rodríguez IM, Salhi Y, Pérez E, Bakaloudi DR, Talukder R, Caramelo B, Morales-Barrera R, De Meulenaere A, Rametta A, Bottelli A, Lefort F, Giannatempo P, Vulsteke C, Carles J, Duran I, Grivas P, de Liaño AG, Robbrecht DGJ, Valderrama BP, van der Noort V, van der Heijden MS. Stockem CF, et al. Among authors: van der noort v. BJC Rep. 2024 Oct 23;2(1):84. doi: 10.1038/s44276-024-00104-3. BJC Rep. 2024. PMID: 39516359 Free PMC article.
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K, van der Wel TJWT, Zeverijn LJ, Geurts BS, Spiekman IAC, de Wit GF, Roepman P, Jansen AML, van der Noort V, Smit EF, Hoeben A, Hendriks LEL, van den Heuvel MM, Piet B, Herder GJM, Hashemi SMS, Gelderblom H, Verheul HMW, Voest EE, de Langen AJ. Verkerk K, et al. Among authors: van der noort v. Clin Cancer Res. 2024 Dec 2;30(23):5323-5332. doi: 10.1158/1078-0432.CCR-24-1925. Clin Cancer Res. 2024. PMID: 39352721 Clinical Trial.
Optimising primary molecular profiling in non-small cell lung cancer.
Schouten RD, Schouten I, Schuurbiers MMF, van der Noort V, Damhuis RAM, van der Heijden EHFM, Burgers JA, Barlo NP, van Lindert ASR, Maas KW, van den Brand JJG, Smit AAJ, van Haarst JMW, van der Maat B, Schuuring E, Blaauwgeers H, Willems SM, Monkhorst K, van den Broek D, van den Heuvel MM. Schouten RD, et al. Among authors: van der noort v. PLoS One. 2024 Jul 31;19(7):e0290939. doi: 10.1371/journal.pone.0290939. eCollection 2024. PLoS One. 2024. PMID: 39083479 Free PMC article.
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Zeverijn LJ, Geurts BS, Battaglia TW, van Berge Henegouwen JM, de Wit GF, Hoes LR, van der Wijngaart H, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Chalabi M, van Herpen CML, Devriese LA, Erdkamp FLG, Labots M, de Jonge MJA, Kerver ED, Bins AD, Leek LVM, Notohardjo JCL, van den Eertwegh AJM, Wessels LFA, Verheul HMW, Gelderblom H, van de Haar J, Voest EE. Zeverijn LJ, et al. Among authors: van der noort v. Clin Cancer Res. 2024 Oct 1;30(19):4339-4351. doi: 10.1158/1078-0432.CCR-24-0480. Clin Cancer Res. 2024. PMID: 39024037
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.
van Berge Henegouwen JM, Zeverijn LJ, Geurts BS, Hoes LR, van der Wijngaart H, van der Noort V, Huitema ADR, de Vos FYF, Grünberg K, Bloemendal HJ, Verheul HMW, Voest EE, Gelderblom H. van Berge Henegouwen JM, et al. Among authors: van der noort v. Clin Cancer Res. 2024 Sep 3;30(17):3937-3943. doi: 10.1158/1078-0432.CCR-23-3917. Clin Cancer Res. 2024. PMID: 38926908
118 results